Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion

Clinical Lung Cancer

Volumn 12, Issue 5, 2011, Pages 307-312

  Masago, Katsuhiro ^a   Togashi, Yosuke ^a   Fukudo, Masahide ^a   Terada, Tomohiro ^a   Irisa, Kaoru ^b   Sakamori, Yuichi ^a   Kim, Young Hak ^a   Mio, Tadashi ^a   Inui, Ken Ichi ^c   Mishima, Michiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Erlotinib; Non small cell lung cancer; Pharmacokinetics; Pleural effusion

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG METABOLITE; ERLOTINIB; GEFITINIB; OSI 420; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG PENETRATION; DRUG PLEURA FLUID LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MALIGNANT PLEURA EFFUSION; MAXIMUM PLASMA CONCENTRATION; PLEURA EFFUSION; PLEURA FLUID;

AGED; AGED, 80 AND OVER; AREA UNDER CURVE; CARCINOMA, NON-SMALL-CELL LUNG; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLEURAL EFFUSION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TIME FACTORS;

EID: 80052475899     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.06.004     Document Type: Article

References (27)

1. J. Mendelsohn, and J. Baselga Epidermal growth factor receptor targeting in cancer Semin Oncol 33 2006 369 385 (Pubitemid 44142736)
2. M. Ranson, L.A. Hammond, and D. Ferry ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial J Clin Oncol 20 2002 2240 2250 (Pubitemid 34441651)
3. J. Baselga, and C.L. Arteaga Critical update and emerging trends in epidermal growth factor receptor targeting in cancer J Clin Oncol 23 2005 2445 2459 (Pubitemid 47050835)
4. F.A. Shepherd, J. Rodrigues Pereira, and T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132 (Pubitemid 41058344)
5. J.R. Johnson, M. Cohen, and R. Sridhara Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen Clin Cancer Res 11 2005 6414 6421 (Pubitemid 41338977)
6. D.M. Jackman, B.Y. Yeap, and N.I. Lindeman Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer J Clin Oncol 25 2007 760 766 (Pubitemid 350002874)
7. P.J. Hesketh, K. Chansky, and A.J. Wozniak Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2 J Thorac Oncol 3 2008 1026 1031
8. R. Lilenbaum, R. Axelrod, and S. Thomas Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 J Clin Oncol 26 2008 863 869 (Pubitemid 351398077)
9. P. Wheatley-Price, K. Ding, and L. Seymour Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21 J Clin Oncol 26 2008 2350 2357
10. W.E. Evans, and C.B. Pratt Effect of pleural effusion on high-dose methotrexate kinetics Clin Pharmacol Ther 23 1978 68 72 (Pubitemid 8290412)
11. J. Li, and P. Gwilt The effect of malignant effusions on methotrexate disposition Cancer Chemother Pharmacol 50 2002 373 382 (Pubitemid 35440526)
12. M. Hidalgo, L.L. Siu, and J. Nemunaitis Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies J Clin Oncol 19 2001 3267 3279 (Pubitemid 32591445)
13. A.R. Tan, X. Yang, and S.M. Hewitt Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor J Clin Oncol 22 2004 3080 3090 (Pubitemid 41103720)
14. J. Ling, K.A. Johnson, and Z. Miao Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers Drug Metab Dispos 34 2006 420 426 (Pubitemid 43290900)
15. M.D. Prados, K.R. Lamborn, and S. Chang Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma Neuro Oncol 8 2006 67 78 (Pubitemid 43154453)
16. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
17. W. Zhang, L.L. Siu, and M.J. Moore Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection J Chromatogr B Analyt Technol Biomed Life Sci 814 2005 143 147 (Pubitemid 40017946)
18. N. Yamamoto, A. Horiike, and Y. Fujisaka Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors Cancer Chemother Pharmacol 61 2008 489 496 (Pubitemid 350275984)
19. P. Frohna, J. Lu, and S. Eppler Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects J Clin Pharmacol 46 2006 282 290 (Pubitemid 43260315)
20. S.B. Howell, B.B. Chu, and W.E. Wung Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions J Clin Invest 67 1981 1161 1170 (Pubitemid 11090557)
21. J.M. Jones, E.A. Olman, and M.J. Egorin A case report and description of the pharmacokinetic behavior of intrapleurally instilled etoposide Cancer Chemother Pharmacol 14 1985 172 174 (Pubitemid 15164822)
22. P.Y. Holoye, D.G. Jeffries, and H.M. Dhingra Intrapleural etoposide for malignant effusion Cancer Chemother Pharmacol 26 1990 147 150 (Pubitemid 20153808)
23. G.V. Bogliolo, R. Lerza, and G.B. Bottino Regional pharmacokinetic selectivity of intrapleural cisplatin Eur J Cancer 27 1991 839 842
24. V.W. Rusch, D. Niedzwiecki, and Y. Tao Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies J Clin Oncol 10 1992 1001 1006
25. R. Lerza, M.O. Vannozzi, and G. Tolino Carboplatin and cisplatin pharmacokinetics after intrapleural combination treatment in patients with malignant pleural effusion Ann Oncol 8 1997 385 391 (Pubitemid 27230981)
26. Y. Tohda, T. Iwanaga, and M. Takada Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer Chemotherapy 45 1999 197 204 (Pubitemid 29213402)
27. S. Monjanel-Mouterde, C. Frenay, and J. Catalin Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions Oncol Rep 7 2000 171 175